Prevention of peptic ulceration in patients receiving NSAIDs.
Non-steroidal anti-inflammatory drugs are widely prescribed and a minority of patients taking them will develop peptic ulceration with the risk of haemorrhage, perforation and death. Recent studies have identified which anti-ulcer agents will prevent such ulceration. This article discusses the problem, how to prevent it and which patients should receive prophylactic treatment.
Ballinger
A
A
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006635:Histamine H2 Antagonists; D016595:Misoprostol; D009853:Omeprazole